Your browser doesn't support javascript.
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates.
Corbett, Kizzmekia S; Werner, Anne P; Connell, Sarah O'; Gagne, Matthew; Lai, Lilin; Moliva, Juan I; Flynn, Barbara; Choi, Angela; Koch, Matthew; Foulds, Kathryn E; Andrew, Shayne F; Flebbe, Dillon R; Lamb, Evan; Nurmukhambetova, Saule T; Provost, Samantha J; Bock, Kevin W; Minai, Mahnaz; Nagata, Bianca M; Ry, Alex Van; Flinchbaugh, Zackery; Johnston, Timothy S; Mokhtari, Elham Bayat; Mudvari, Prakriti; Henry, Amy R; Laboune, Farida; Chang, Becky; Porto, Maciel; Wear, Jaclyn; Alvarado, Gabriela S; Boyoglu-Barnum, Seyhan; Todd, John-Paul M; Bart, Bridget; Cook, Anthony; Dodson, Alan; Pessaint, Laurent; Steingrebe, Katelyn; Elbashir, Sayda; Sriparna, Manjari; Pekosz, Andrew; Andersen, Hanne; Wu, Kai; Edwards, Darin K; Kar, Swagata; Lewis, Mark G; Boritz, Eli; Moore, Ian N; Carfi, Andrea; Suthar, Mehul S; McDermott, Adrian; Roederer, Mario.
  • Corbett KS; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Werner AP; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Connell SO; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Gagne M; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Lai L; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Moliva JI; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Department of Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, GA, USA.
  • Flynn B; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Choi A; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Koch M; Moderna, Cambridge, MA, USA.
  • Foulds KE; Moderna, Cambridge, MA, USA.
  • Andrew SF; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Flebbe DR; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Lamb E; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Nurmukhambetova ST; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Provost SJ; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Bock KW; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Minai M; Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Nagata BM; Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Ry AV; Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Flinchbaugh Z; Bioqual, Rockville, MD, USA.
  • Johnston TS; Bioqual, Rockville, MD, USA.
  • Mokhtari EB; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Mudvari P; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Henry AR; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Laboune F; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Chang B; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Porto M; Bioqual, Rockville, MD, USA.
  • Wear J; Bioqual, Rockville, MD, USA.
  • Alvarado GS; Bioqual, Rockville, MD, USA.
  • Boyoglu-Barnum S; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Todd JM; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Bart B; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Cook A; Bioqual, Rockville, MD, USA.
  • Dodson A; Bioqual, Rockville, MD, USA.
  • Pessaint L; Bioqual, Rockville, MD, USA.
  • Steingrebe K; Bioqual, Rockville, MD, USA.
  • Elbashir S; Bioqual, Rockville, MD, USA.
  • Sriparna M; Moderna, Cambridge, MA, USA.
  • Pekosz A; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Andersen H; Department of Microbiology and Immunology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA.
  • Wu K; Bioqual, Rockville, MD, USA.
  • Edwards DK; Moderna, Cambridge, MA, USA.
  • Kar S; Moderna, Cambridge, MA, USA.
  • Lewis MG; Bioqual, Rockville, MD, USA.
  • Boritz E; Bioqual, Rockville, MD, USA.
  • Moore IN; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Carfi A; Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Suthar MS; Moderna, Cambridge, MA, USA.
  • McDermott A; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Department of Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, GA, USA.
  • Roederer M; Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA.
Nat Immunol ; 22(10): 1306-1315, 2021 10.
Article in English | MEDLINE | ID: covidwho-1366822
ABSTRACT
B.1.351 is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant most resistant to antibody neutralization. We demonstrate how the dose and number of immunizations influence protection. Nonhuman primates received two doses of 30 or 100 µg of Moderna's mRNA-1273 vaccine, a single immunization of 30 µg, or no vaccine. Two doses of 100 µg of mRNA-1273 induced 50% inhibitory reciprocal serum dilution neutralizing antibody titers against live SARS-CoV-2 p.Asp614Gly and B.1.351 of 3,300 and 240, respectively. Higher neutralizing responses against B.1.617.2 were also observed after two doses compared to a single dose. After challenge with B.1.351, there was ~4- to 5-log10 reduction of viral subgenomic RNA and low to undetectable replication in bronchoalveolar lavages in the two-dose vaccine groups, with a 1-log10 reduction in nasal swabs in the 100-µg group. These data establish that a two-dose regimen of mRNA-1273 will be critical for providing upper and lower airway protection against major variants of concern.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Primates / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Female / Humans / Male Language: English Journal: Nat Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article Affiliation country: S41590-021-01021-0

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Primates / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Female / Humans / Male Language: English Journal: Nat Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article Affiliation country: S41590-021-01021-0